Lyrica approved for use in GAD

The licensed indications for Lyrica (pregabalin) have been extended to include the treatment of generalised anxiety disorder (GAD).

The recommended adult dose for use in the new indication is 150 to 600mg daily in two or three divided doses. The dose should be started at 150mg daily then, based on the patient's response, titrated in 150mg daily increments at weekly intervals to a maximum of 600mg daily.

Relief of symptoms may be expected within one week. The need for continued treatment should be reassessed regularly.

Lyrica is also indicated for use as adjunctive therapy in epilepsy for partial seizures with or without secondary generalisation and is available in seven different strengths: 25mg, 50mg, 75mg, 100mg, 150mg, 200mg and 300mg.

Further information: Pfizer Ltd, Walton Oaks, Dorking Road, Tadworth, Surrey KT20 7NS. Tel: (01304) 616161.


Read these next

Lyrica (pregabalin) oral solution launched

Lyrica (pregabalin) oral solution launched

An oral liquid formulation of Lyrica (pregabalin) is...


Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS bulletins

News and updates straight to your inbox.

Prescribing Update: Fortnightly news bulletin
Alert:
Urgent prescribing updates
Spotlight: Disease-themed monthly round-up

Sign me up

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases